Grown Rogue International (GRUSF) Net Cash Flow (2011 - 2026)
Grown Rogue International's (GRUSF) quarterly Net Cash Flow came in at $2.3 million in Q1 2026, down 31.03% year-on-year from $3.4 million in Q1 2025, and up 100.0% quarter-over-quarter from -$8411.9 billion in Q4 2025.
Grown Rogue International (GRUSF) Net Cash Flow (2011 - 2026) Analysis & Trends
Grown Rogue International's Net Cash Flow history runs 15 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- On a quarterly basis, Net Cash Flow fell 31.03% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was -$8411.9 billion, a 8379756270.87% decrease from a year earlier, with the FY2025 full-year figure at $6.5 million, up 516.09% from the prior year.
- Net Cash Flow advanced to $2.3 million in Q1 2026 per GRUSF's latest filing, from -$8411.9 billion in the prior quarter.
- Across five years, Net Cash Flow topped out at $4.0 million in Q4 2023 and bottomed at -$8411.9 billion in Q4 2025.
- The 5-year median for Net Cash Flow is $548914.0 (2022), against an average of -$764.7 billion.
- Across the five-year window, Net Cash Flow jumped 157.39% in 2023 and plunged 1292022235.12% in 2025, its largest moves.
- Year by year, Net Cash Flow stood at $548914.0 in 2022, then jumped by 621.51% to $4.0 million in 2023, then plunged by 116.44% to -$651061.9 in 2024, then plunged by 1292022235.12% to -$8411.9 billion in 2025, then jumped by 100.0% to $2.3 million in 2026.
- Per Business Quant, the three latest GRUSF Net Cash Flow figures stand at $2.3 million (Q1 2026), -$8411.9 billion (Q4 2025), and $3.4 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -277.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -112.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 2.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.33 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Dec 31, 2025 | -8,411.87 Bn |
| Dec 31, 2025 | -8,411.87 Bn |
| Mar 31, 2025 | 3.38 Mn |
| Mar 31, 2025 | 3.38 Mn |
| Dec 31, 2024 | -651,061.93 |
| Dec 31, 2024 | -651,061.93 |
| Sep 30, 2024 | -1.41 Mn |
| Sep 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | -1.41 Mn |
| Mar 31, 2024 | 1.97 Mn |
| Mar 31, 2024 | 1.97 Mn |
| Oct 31, 2023 | 3.96 Mn |
| Oct 31, 2023 | 3.96 Mn |
| Apr 30, 2023 | 300,769.00 |
| Apr 30, 2023 | 300,769.00 |
| Jan 31, 2023 | 1.41 Mn |
| Jan 31, 2023 | 1.41 Mn |